Fingolimod failure in progressive MS INFORMS future trials

被引：0
|
作者：
Andrew L. Smith
Jeffrey A. Cohen
机构：
[1] Mellen Center for Multiple Sclerosis Treatment and Research in the Neurological Institute,
[2] Cleveland Clinic,undefined
来源：
Nature Reviews Neurology | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Fingolimod is approved for the treatment of relapsing–remitting multiple sclerosis (MS), and evidence suggests that it has neuroprotective effects. The recent INFORMS phase III trial in primary progressive MS demonstrated no beneficial effects of fingolimod on disability progression or whole-brain atrophy, but provides important information for future therapeutic development.
引用
收藏
页码：253 / 254
页数：1
相关论文
共 50 条
  • [1] Fingolimod failure in progressive MS INFORMS future trials
    Smith, Andrew L.
    Cohen, Jeffrey A.
    NATURE REVIEWS NEUROLOGY, 2016, 12 (05) : 253 - 254
  • [2] Treatment trials in progressive MS—current challenges and future directions
    Marcus W. Koch
    Gary Cutter
    Peter K. Stys
    V. Wee Yong
    Luanne M. Metz
    Nature Reviews Neurology, 2013, 9 : 496 - 503
  • [3] Treatment trials in progressive MS-current challenges and future directions
    Koch, Marcus W.
    Cutter, Gary
    Stys, Peter K.
    Yong, V. Wee
    Metz, Luanne M.
    NATURE REVIEWS NEUROLOGY, 2013, 9 (09) : 496 - 503
  • [4] Trial design and baseline data of the INFORMS (fingolimod in patients with primary progressive multiple sclerosis) study
    Polman, C. H.
    Cree, B.
    Freedman, M. S.
    Hartung, H. -P.
    Holdbrook, F.
    Kappos, L.
    Kornyeyeva, E.
    Lubetzki, C.
    Lublin, F. D.
    Miller, D. H.
    Montalban, X.
    Pirozzi, C.
    Weiner, H. L.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 437 - 438
  • [5] Study Design and Baseline Characteristics of the INFORMS Study: Fingolimod in Patients with Primary Progressive Multiple Sclerosis
    Miller, David
    Cree, Bruce
    Dalton, Catherine
    Freedman, Mark
    Hartung, Hans
    Kappos, Ludwig
    Lubetzki, Catherine
    Lublin, Fred
    MacManus, David
    Montalban, Xavier
    Weiner, Howard
    Wolinsky, Jerry
    De Vera, Ana
    Kornyeyeva, Elena
    Li, Bingbing
    Pirozzi, Claudia
    von Rosenstiel, Philipp
    Polman, Chris
    NEUROLOGY, 2013, 80
  • [6] Progressive MS trials: Lessons learned
    Tur, Carmen
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (12) : 1583 - 1592
  • [7] Outcome measures in progressive MS trials
    Marrie, R. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 52 - 54
  • [8] Outcome Measures for Trials of Progressive MS
    Fox, R.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 15 - 15
  • [9] Differences between Progressing and Stable Patients with Primary Progressive Multiple Sclerosis in INFORMS (Fingolimod vs Placebo)
    Wolinsky, Jerry S.
    Lublin, Fred
    Weiner, Howard
    Li, Bingbing
    Haering, Dieter A.
    Merschhemke, Martin
    Putzki, Norman
    Miller, David H.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 15 - 15
  • [10] Efficacy of fingolimod treatemnt in patients with progressive forms of MS and high disability
    Petrou, Panayiota
    Vaknin, A. D. I.
    Abramsky, Oded
    Ben Hur, Tamir
    Karussis, Dimitrios
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 71 - 71
12345